Floorless Preferred Stock/Debenture Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jjs_ynot who wrote (1315)	7/8/2001 2:31:27 AM
From: BDR	of 1438

Unless there has been another amendment it looks like TMGU will lose its license for its only product, Remune, by August, 2001. Remune is still in trials and I don't see that they have marketing approval from Thailand. I may be missing something but this company looks like it's on the critical list. Trinity Medical Group USA, Inc. Announces Amendment of License Agreement With The Immune Response Corporation. Issue: Oct 9, 2000 SAN RAFAEL, Calif., Oct. 9 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC: TMGU) announces the amendment of its license agreement for REMUNE(TM) with The Immune Response Corporation that extends the time requirement for marketing approval of REMUNE by Thailand Authorities. The License and Collaboration Agreement between the Company and The Immune Response Corporation had previously set Dec. 31, 2000 as a possible termination date of the agreement if Thailand governing health authorities had not granted the required marketing approval of REMUNE by then. The amendment removes that time requirement and the earliest possible termination date is now August 2001.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next